09/05 - Periodontal Pathogens Flashcards
What is the non-specific plaque hypothesis?
- plaque control important in periodontal treatment
- all plaque bacteria considered bad
- any accumulation of micro-organisms at or below the gingival margin causes inflammation
What is the specific plaque hypothesis?
- specific organisms in dental plaque are the etiological agents
- microbial composition of disease sites different from healthy sites
- local debridement and systemic antibioitcs could control LAP
What are the prerequisites for disease initiation and progression?
- VIRULENT PERIODONTAL PATHOGEN: P. gingivalis with type II and IV fimA genotypes; virulence factors; right location in the site (adjacent to epithelium, apical part of the pocket)
- LOCAL ENVIRONMENT: colonization by beneficial species dilutes and inhibits pathogens; effect of local “regulon”/subgingival environment (iron increases outer membrane protein expression in P. gingivalis and S. cristatus can inhibit fimA expression)
- HOST SUSCEPTIBILITY: HIV infection; diabetes; smoking
What are the 4 different ways through which pathogens colonize?
- ADHESINS ON BACTERIA BIND HOST RECEPTORS: type I or IV collagen, sialic acid, galactosyl residues; bacteria have fimbriae or outer membrane proteins
- COAGGREGATION
- NUTRIENT UTILIZATION: Veillonella uses lactate made by streptococci; Campylobacter uses formate made by Selenomonas; Porphyromonas uses hermin from blood in sulcus
- COMPETITIVE INHIBITION: bacteriocins; hydrogen perioxide production
What are the 3 ways through which pathogens overcome host defenses?
- DESQUAMATION OF EPITHELIUM: invade epithelium and bind to underlying cells
- PREVENT ANTIBODY-BINDING: IgG and IgA proteases; mimic host antigens
- PREVENT PHAGOCYTIC CELLS: leukotoxin; non-lethal suppression of immune cells
The World Workshop in 1996 designated 3 pathogens. What are they?
- P. gingivalis
- A. actinomycetemcomitans
- T. forsythia
Is Actinobacillus actinomycetemcomitans (AA) motile? Gram positive or negative? How does it get its energy? Aerobic or anaerobic? Shape of bacteria and colonies?
- non-motile
- gram-negative
- saccharolytic (breaks down carbs for energy)
- capnophlic (thrive in high CO2)
- round-ended rod; star-shaped colonies
What is the evidence of AA as a pathogen based on association?
- high numbers associated with agressive periodontisis
- detected in active sites
- detected in prospective studies
What is the evidence of AA as a pathogen based on elimination?
- elimination or suppression resulted in successful therapy
- recurrent lesions harbor the species
What is the evidence of AA as a pathogen based on host response? It also inhibits ___ and induces ___.
- high levels of systemic and local antibody response
- inhibits growth of commensals (S. sanguis)
- induces disease in animal models
What is the evidence of AA as a pathogen based on virulence factors?
- tissue invasive (epithelial and endothelial cells)
- leukotoxin
- fibroblast inhibiting factor
- endotoxin
- collagenase
What is the evidence AGAINST AA being a pathogen?
- not seen in all cases of aggressive periodontitis
- seen in periodontally healthy subjects
- genetic analysis of the leukotoxin gene (13 clusters identified; II seen in severe disease; XII and XIV associated with health)
- AA with 530 bp deletion is 23x more likely to be disease-associated than AA with full length promoter region
There are ___ serotypes of AA which are based on ___. ___ are the dominant antigens.
- 5
- polysaccharides on the surface of an organism
- serotype-specific surface antigens (SPA)
Serotype ___ of AA is most commonly associated with localized aggressive periodontitis in the USA. It has a role in resistance to ___.
- b
- resistance to phagocytosis and killing by PMNs
Serotype ___ of AA is health-associated in Finland and disease-associated in Japan.
a
For an AA infection, ___ and ___ approach is vital to treatment. ___ and ___ are effective in reducing bacterial load. ___ approach is required to eliminate tissue reservoirs.
- mechanical
- chemotherapeutic
- amoxicillin 500 mg
- metronidazole 250 mg
- surgical